NEW POTENT HETEROCYCLIC BISPHOSPHONATE API (ZOLEDRONIC ACID): A REVIEW

Zoledronic acid is a new, highly potent bisphosphonate drug. Bisphosphonates is a class of chemical compounds finding extensive medical applications against bone disorders including osteoporosis, Pagets’ disease, etc. Non-N-containingmembers include etidronate, clodronate Andtiludronate, while N-containing bisphosphonates include active pharmaceutical compounds Such as pamidronate, neridronate, olpadronate, alendronate, ibandronate, risedronate and zoledronate. The present study covers 20 years of analytical researchon this groupofcompounds, focusing on bioanalytical and pharmaceutical

[1]  H. Fleisch,et al.  The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals , 1973, Calcified Tissue Research.

[2]  O. Sadik,et al.  Stability Indicating Ion‐Pair HPLC Method for the Determination of Risedronate in a Commercial Formulation , 2004 .

[3]  R. Kandel,et al.  Partial chondroprotective effect of zoledronate in a rabbit model of inflammatory arthritis. , 1999, The Journal of rheumatology.

[4]  N. Binkley,et al.  Zoledronate Prevents the Development of Absolute Osteopenia Following Ovariectomy in Adult Rhesus Monkeys , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[5]  S. Kautiainen,et al.  Transformation of bisphosphonates into insoluble material in human blood in vitro. , 1998, Methods and findings in experimental and clinical pharmacology.

[6]  P. Degen,et al.  An enzyme inhibition assay for the quantitative determination of the new bisphosphonate zoledronate in plasma. , 1997, Journal of pharmaceutical and biomedical analysis.

[7]  L. Widler,et al.  Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models. , 1997, Pharmacology & toxicology.

[8]  K. Jaeggi,et al.  Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[9]  J. Lin,et al.  Role of calcium in plasma protein binding and renal handling of alendronate in hypo- and hypercalcemic rats. , 1993, The Journal of pharmacology and experimental therapeutics.

[10]  B. Matuszewski,et al.  Improved determination of the bisphosphonate alendronate in human plasma and urine by automated precolumn derivatization and high-performance liquid chromatography with fluorescence and electrochemical detection. , 1992, Journal of chromatography.

[11]  P. Daley-Yates,et al.  Assay of 1-hydroxy-3-aminopropylidene-1,1-bisphosphonate and related bisphosphonates in human urine and plasma by high-performance ion chromatography. , 1989, Journal of chromatography.

[12]  Bijvoet Ol,et al.  Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. , 1986 .